Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Meiji Seika Pharma Pres. Matsuo to Helm Holding Firm
May 14, 2014
- Eisai Sales Up 4.7% Thanks to Humira, Halaven Growth
May 14, 2014
- Santen Acquires Merck’s Eye Drugs in Japan, Key Markets
May 14, 2014
- 4 Major Wholesalers’ Average Operating Margin Tops 1% Mark, Signaling Biz Recovery
May 13, 2014
- Astellas FY2013 Sales Up 16% on Rosy Revenues from Xtandi, Betanis
May 13, 2014
- March Ethical Drug Sales Zoom 13.8% on Pre-Tax Hike Demand: Crecon Report
May 13, 2014
- Astellas Pres. “Aware” of Rumored Marriage with Daiichi Sankyo, but Denies Any Merger at This Time
May 13, 2014
- Questionnaire Survey of Chronic Myeloid Leukemia Patients Finds 30 Unreported ADRs: Novartis
May 13, 2014
- Nippon Kayaku Predicts Remicade Biosimilar Sales of 1.1 Billion Yen for FY2014
May 13, 2014
- MTPC Plans to Reduce Costs by 10 Billion Yen by FY2016
May 12, 2014
- FY2013 Japan Ethical Drug Market Crosses 10 Trillion Yen Mark for 1st Time: IMS
May 12, 2014
- Shionogi Makes Record Operating, Ordinary Profits
May 12, 2014
- LEO Pharma Takes Over Marketing Authorization to Dovonex
May 12, 2014
- Eisai to Develop Novel Inflammatory Bowel Disease Treatment with University of Tsukuba
May 12, 2014
- Kissei Aims to Maintain Non-Consolidated Sales, Launch Hyperphosphatemia Treatment: New Midterm Plan
May 12, 2014
- DSP to Execute Option Rights to Codevelop Cerebral Infarction Cell Therapy in April-Sept.
May 9, 2014
- MTPC to Push Tenelia, Canaglu to Compete in Diabetes Field
May 9, 2014
- DSP Sales Up 11.5% in FY2013; Latuda, Softer Yen Eclipse Japan Dip
May 9, 2014
- MTPC Logs 8.4% Net Profit Rise, 1.6% Sales Decline
May 9, 2014
- Takeda FY2013 Sales Up 8.6% on Buoyant Azilva, Pantoprazole
May 9, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…